Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals.

OBJECTIVE To determine the efficacy of a daily dose of 81 mg aspirin in primary thrombosis prevention in asymptomatic, persistently antiphospholipid antibody (aPL)-positive individuals (those with positive aPL but no vascular and/or pregnancy events). METHODS The Antiphospholipid Antibody Acetylsalicylic Acid (APLASA) study was a multicenter, randomized, double-blind, placebo-controlled clinical trial in which asymptomatic, persistently aPL-positive individuals were randomized to receive a daily dose of 81 mg of aspirin or placebo. In a separate observational and parallel study, asymptomatic, persistently aPL-positive individuals who were taking aspirin or declined randomization were followed up prospectively. RESULTS In the APLASA study, 98 individuals were randomized to receive aspirin or placebo (mean +/- SD followup period 2.30 +/- 0.95 years), of whom 48 received aspirin and 50 received placebo. In the observational study, 74 nonrandomized individuals were followed up prospectively (mean +/- SD followup period 2.46 +/- 0.76 years); 61 received aspirin and 13 did not. In the APLASA study, the acute thrombosis incidence rates were 2.75 per 100 patient-years for aspirin-treated subjects and 0 per 100 patient-years for the placebo-treated subjects (hazard ratio 1.04, 95% confidence interval 0.69-1.56) (P = 0.83). Similarly, in the observational study, the acute thrombosis incidence rates were 2.70 per 100 patient-years for aspirin-treated subjects and 0 per 100 patient-years for those not treated with aspirin. All but 1 patient with thrombosis in either study had concomitant thrombosis risk factors and/or systemic autoimmune disease at the time of thrombosis. CONCLUSION Our results suggest that asymptomatic, persistently aPL-positive individuals do not benefit from low-dose aspirin for primary thrombosis prophylaxis, have a low overall annual incidence rate of acute thrombosis, and develop vascular events when additional thrombosis risk factors are present.

[1]  D. Erkan.  Lupus and thrombosis. , 2006, The Journal of rheumatology.

[2]  M. Huisman,et al.  Aspirin in the prevention and treatment of venous thromboembolism , 2006 .

[3]  S. Goldstein.  Cardiac Remodeling: Mechanism and Treatment , 2006 .

[4]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[5]  Gianni Tognoni,et al.  Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials , 2006, JAMA.

[6]  C. Mok.  Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus , 2006, Scandinavian journal of rheumatology.

[7]  F. Rosendaal,et al.  A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study) , 2006, Journal of thrombosis and haemostasis : JTH.

[8]  R. de Caterina,et al.  Aspirin overprescription in primary cardiovascular prevention. , 2006, Thrombosis research.

[9]  A. Weyrich,et al.  Classification of venous thromboembolism (VTE) , 2005 .

[10]  K. Hamulýak,et al.  Classification of venous thromboembolism (VTE) , 2005, Journal of thrombosis and haemostasis : JTH.

[11]  Sidney C. Smith,et al.  The lady aspirin for cardiovascular disease , 2005, The Lancet.

[12]  I. Bruce,et al.  Therapy Insight: systemic lupus erythematosus as a risk factor for cardiovascular disease , 2005, Nature Clinical Practice Cardiovascular Medicine.

[13]  M. Martinuzzo,et al.  A prospective study of antibodies to β2‐glycoprotein I and prothrombin, and risk of thrombosis , 2005, Journal of thrombosis and haemostasis : JTH.

[14]  C. Laskin,et al.  Antiphospholipid syndrome in systemic lupus erythematosus: is the whole greater than the sum of its parts? , 2005, Rheumatic diseases clinics of North America.

[15]  J. Manson,et al.  A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women , 2005, The New England journal of medicine.

[16]  J. Rodríguez-Martorell,et al.  Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. , 2004, The Journal of rheumatology.

[17]  D. Levy,et al.  Genome-Wide Scan for Pulse Pressure in the National Heart, Lung and Blood Institute’s Framingham Heart Study , 2004, Hypertension.

[18]  P. D. de Groot,et al.  Antiphospholipid antibodies: update on detection, pathophysiology, and treatment , 2004, Current opinion in hematology.

[19]  C. Hennekens,et al.  An update on aspirin in the primary prevention of cardiovascular disease. , 2003, Archives of internal medicine.

[20]  Y. Shoenfeld,et al.  Prophylaxis of the antiphospholipid syndrome: a consensus report , 2003, Lupus.

[21]  T. Barbui,et al.  Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. , 2003, Blood.

[22]  T. Barbui,et al.  Antiphospholipid antibodies and thrombosis: strength of association. , 2003, The hematology journal : the official journal of the European Haematology Association.

[23]  L. Magder,et al.  Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. , 2002, The Journal of rheumatology.

[24]  M. Peterson,et al.  A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. , 2002, Rheumatology.

[25]  James F Sallis,et al.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.

[26]  J. Buyon,et al.  High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. , 2001, Arthritis and rheumatism.

[27]  F. Sarasin,et al.  Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. , 2000, Archives of internal medicine.

[28]  J. Danesh,et al.  Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial , 2000, The Lancet.

[29]  W A Wilson,et al.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. , 1999, Arthritis and rheumatism.

[30]  E. Hachulla,et al.  Longitudinal determination of antiphospholipid antibodies in lupus patients without previous manifestations of antiphospholipid syndrome. A prospective study. , 1999, The Journal of rheumatology.

[31]  G. Hughes,et al.  Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients , 1998, Lupus.

[32]  E. Meese,et al.  Multiple human endogenous retrovirus (HERV-K) loci with gag open reading frames in the human genome. , 1997, Cytogenetics and cell genetics.

[33]  F. Rosendaal,et al.  Thrombosis in the Young: Epidemiology and Risk Factors. A Focus on Venous Thrombosis , 1997, Thrombosis and Haemostasis.

[34]  T. Barbui,et al.  Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. , 1996, The American journal of medicine.

[35]  I. Scharrer,et al.  Criteria for the Diagnosis of Lupus Anticoagulants: An Update , 1995, Thrombosis and Haemostasis.

[36]  G. Hughes,et al.  The management of thrombosis in the antiphospholipid-antibody syndrome. , 1995, The New England journal of medicine.

[37]  R. Collins,et al.  Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials , 1994, BMJ.

[38]  Radcliffe Infirmary,et al.  Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients , 1994, BMJ.

[39]  P. D. de Groot,et al.  Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. , 1993, Annals of the rheumatic diseases.

[40]  M. Stampfer,et al.  Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis , 1992, Annals of Internal Medicine.

[41]  M. Rosove,et al.  Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients , 1992, Annals of Internal Medicine.

[42]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.